262450-65-7 Usage
Description
3-Bromo-5-methoxybenzaldehyde is an organic compound characterized by the presence of a bromo and methoxy group attached to a benzene ring, with a formyl group (-CHO) at the aldehyde position. This unique structure endows it with versatile chemical properties, making it a valuable intermediate in the synthesis of various pharmaceutical and chemical compounds.
Uses
Used in Pharmaceutical Industry:
3-Bromo-5-methoxybenzaldehyde is used as a key intermediate in the synthesis of novel scaffolds, which have led to the discovery of potent and selective inhibitors of Dihydrofolate Reductase (DHFR). DHFR inhibitors are important in the treatment of Cryptosporidiosis, a parasitic disease that can cause severe diarrhea and malnutrition, particularly in immunocompromised individuals.
Used in Medicinal Chemistry Research:
3-Bromo-5-methoxybenzaldehyde is also utilized in the synthesis of Tetrahydrobenzoxepino[2,3,4-ij]isoquinolines derivatives. These compounds have been found to act as Dopamine Receptor ligands, playing a crucial role in the modulation of dopamine signaling pathways. Dopamine receptors are involved in various physiological processes, including movement, motivation, and reward, making them an important target for the development of drugs to treat neurological and psychiatric disorders such as Parkinson's disease, schizophrenia, and addiction.
Check Digit Verification of cas no
The CAS Registry Mumber 262450-65-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,2,4,5 and 0 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 262450-65:
(8*2)+(7*6)+(6*2)+(5*4)+(4*5)+(3*0)+(2*6)+(1*5)=127
127 % 10 = 7
So 262450-65-7 is a valid CAS Registry Number.
262450-65-7Relevant articles and documents
NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
-
Paragraph 0138-0140; 0479-0481, (2020/08/25)
Compound of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y and G are as defined in the description, and their use in the manufacture of medicaments.
Design and synthesis of novel meta-linked phenylglycine macrocyclic FVIIa inhibitors
Richter, Jeremy M.,Cheney, Daniel L.,Bates, J. Alex,Wei, Anzhi,Luettgen, Joseph M.,Rendina, Alan R.,Harper, Timothy M.,Narayanan, Rangaraj,Wong, Pancras C.,Seiffert, Dietmar,Wexler, Ruth R.,Priestley, E. Scott
supporting information, p. 67 - 72 (2017/12/12)
Two novel series of meta-linked phenylglycine-based macrocyclic FVIIa inhibitors have been designed to improve the rodent metabolic stability and PK observed with the precursor para-linked phenylglycine macrocycles. Through iterative structure-based design and optimization, the TF/ FVIIa Ki was improved to subnanomolar levels with good clotting activity, metabolic stability, and permeability.
CYCLIC AMINES AS BROMODOMAIN INHIBITORS
-
Paragraph 0512, (2014/05/25)
The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
